Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

Leukemia

Volumn 15, Issue 3, 2001, Pages 342-347

  Topaly, J ^a   Zeller, W J ^a   Fruehauf, S ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic myelogenous leukemia; Combination drug therapy; Median effect method of Chou and Talalay; STI571; Synergism

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; ARA CELL; BCR ABL PROTEIN; CD34 ANTIGEN; CYTARABINE; CYTOTOXIC AGENT; ETOPOSIDE; HYDROXYUREA; IMATINIB; MAFOSFAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; TETRAZOLIUM; UNCLASSIFIED DRUG; VEPESID J;

ARTICLE; BLAST CELL CRISIS; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CELL STRAIN HL 60; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL;

EID: 0035080416     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402041     Document Type: Article

References (32)

1. Chronic myeloid leukemia
2. Clinical efficacy and safety of an Abl-specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
3. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors
4. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice
5. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
6. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide
7. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay
8. Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukemia cell lines
9. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia
10. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
11. A minute chromosome in chronic granulocytic leukemia
12. A new consistant chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine, fluorescence and Giemsa staining
13. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity
14. Leukemia and the disruption of normal hematopoiesis
15. Molecular pathogenesis of chronic myeloid leukemia: Implications for new therapeutic strategies
16. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
17. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
18. Ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block
19. Regulation of the Fas apoptotic cell death pathway by Abl
20. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
21. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of bcr/abl positive cells
22. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
23. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins
24. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
25. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis
26. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL
27. Induction of resistance to the abelson inhibitor STI571 in human leukemic cells through gene amplification
28. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the signal transduction inhibitor STI571: Mechanisms of resistance
29. Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM
30. Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy
31. Synergistic action of vincristine and adriamycin in the treatment of experimental rat leukemia L5222
32. More than additive toxicity of the combination of 1-methyl-1-nitrosourea plus 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat